Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma The patient provides written informed consent to participate in the study 2. Male or female patient aged 18 to 65 years 3. Documented diagnosis of asthma 4. Forced Expiratory Volume in One Second (FEV1) between 50% and 80% of the predicted value 5. Patient judged by the investigator to be in otherwise good stable health based on medical history, physical examination, and routine laboratory data 6. Female participants must have a negative pregnancy test at screening visit 7. Males must agree to use barrier contraception while on study medication and for 90 days after taking the last dose of study medication  Pregnant or lactating women 2. Female subjects on hormone replacement therapy or hormonal contraceptives 3. Suffering from relevant lung diseases (other than asthma) causing impairment in lung function 4. Past smoker with a history of ≥10 pack per year or current smoker 5. Recent change in the patient's usual asthma treatment 6. Patients with risk factors for asthma exacerbation during the study, including (any of the following) Current requirement for > 8 puffs per day of reliever medication Hospitalization for asthma Treatment with systemic corticosteroid therapy within 3 months 7. Evidence of current or recent neoplastic disease 8. Clinically significant cardiovascular, haematological, endocrine, neurological, gastrointestinal, psychiatric, metabolic, immunologic, infectious, hepatic, renal, gynaecological disease or other condition that the investigator considers detrimental to the patient's participation in the study or that may prevent the successful completion of the study 9. Positive serology for an infectious disease (including hepatitis B or C) at screening and known case of human immunodeficiency virus [HIV] 10. Patients who have been hospitalized for any psychiatric illness in the past year, or are diagnosed with major depression 11. Clinically significant ECG Abnormality at baseline 12. Patients with documented or suspected or current history of alcohol and drug abuse 13. Patients who have undergone lung surgery in the previous year 14. Participation in an investigational drug trial during 30 days preceding screening